Join
Live feed
·
NEWSReleasevia Quantisnow
Concert Pharmaceuticals Inc. logo

Concert Pharmaceuticals Says FDA Determined That Deuruxolitinib Will Maintain Its Breakthrough Therapy Designation

ByQuantisnow·Wall Street's wire, on your screen.
CNCE· Concert Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CNCE (Concert Pharmaceuticals Inc.) and more on Quantisnow.